New Management Strategies in Heart Failure

摘要: Despite >100 clinical trials, only 2 new drugs had been approved by the US Food and Drug Administration for treatment of chronic heart failure in more than a decade: aldosterone antagonist eplerenone 2003 fixed dose combination hydralazine-isosorbide dinitrate 2005. In contrast, 2015 has witnessed approval drugs, both with reduced ejection fraction: ivabradine another drug, sacubitril/valsartan or LCZ696. Seemingly overnight, range therapeutic possibilities, evoking physiological mechanisms, promise great hope disease that often carries prognosis worse many forms cancer. Importantly, newly available therapies represent culmination basic translational research actually spans decades. This review will summarize newer currently being used failure, as well strategies increasingly explored their utility during stages syndrome.